Aromatase Inhibitors, non steroideal — Competitive Intelligence Brief

Aromatase Inhibitors, non steroideal (Aromatase Inhibitors, non steroideal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase Inhibitors, non-steroideal. Area: Oncology.

phase 2 Aromatase Inhibitors, non-steroideal Aromatase Oncology Small molecule

Target snapshot

Aromatase Inhibitors, non steroideal (Aromatase Inhibitors, non steroideal) — Fondazione Sandro Pitigliani. Non-steroidal aromatase inhibitors block the enzyme aromatase, reducing estrogen production in postmenopausal women.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aromatase Inhibitors, non steroideal TARGET	Aromatase Inhibitors, non steroideal	Fondazione Sandro Pitigliani	phase 2	Aromatase Inhibitors, non-steroideal	Aromatase
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Aromasin	exemestane	Pfizer	marketed	Aromatase Inhibitor [EPC]	Aromatase	1999-01-01
Femara	letrozole	Novartis AG	marketed	Aromatase Inhibitor [EPC]	aromatase enzyme	1997-07-25
Arimidex	anastrozole	AstraZeneca	marketed	Aromatase inhibitor	Aromatase enzyme	1995-12-27
ANASTROZOLE	ANASTROZOLE		marketed	Aromatase Inhibitor [EPC]	aromatase	1995-01-01
Actinex	MASOPROCOL		marketed	masoprocol	Aromatase	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase Inhibitors, non-steroideal class)

1. Fondazione Sandro Pitigliani · 1 drug in this class